No Established Guideline Exists for ICG in Breast Cancer Margin Assessment
There is currently no formal clinical guideline for using indocyanine green (ICG) as an adjunct to margin assessment in breast-conserving surgery for breast cancer. The ACR Appropriateness Criteria for imaging after breast surgery 1 does not address ICG fluorescence imaging, and the FDA-approved indications for ICG 2 are limited to hepatic function studies and ophthalmic angiography—not intraoperative margin assessment in breast surgery.
Current Evidence Status
The use of ICG for breast cancer margin assessment remains investigational. While multiple research studies have explored this application, the evidence is:
- Inconsistent in methodology: Studies vary widely in ICG dosing (0.125 mg/kg to 2 mg/kg) and timing of administration (intraoperative at anesthesia induction vs. 2-24 hours preoperatively) 3, 4, 5
- Limited in validation: The largest prospective trial (BREASTIFLU-1) is still ongoing with results expected in 2026 3
- Variable in performance: Reported sensitivity ranges from 67-88% and specificity from 74-93%, depending on dose and timing 4
Research-Based Protocols Under Investigation
Dosing Strategies Being Studied:
Intraoperative administration:
- 0.125-0.25 mg/kg IV at anesthesia induction 3
Preoperative administration:
Preliminary Findings:
A 2024 study 4 comparing doses found that 1 mg/kg provided higher sensitivity (87.5%) but lower specificity (74.4%) compared to 0.5 mg/kg (sensitivity 66.7%, specificity 93.3%). This trade-off suggests higher doses may increase false positives while capturing more true positive margins.
Critical Limitations
The specificity of ICG fluorescence is problematic: Studies consistently show ICG accumulates in both malignant and benign breast tissue, leading to false-positive margin assessments 4, 6. One study found ICG detected abnormal fluorescence in 11.6% of patients, but only 60% of these had actual residual carcinoma—the rest had benign adenosis 5.
ICG performs worse than frozen section analysis: While sensitivity is comparable (81-82%), specificity is significantly lower (76% vs. 95%) 4. This means ICG would lead to more unnecessary re-excisions than current standard techniques.
Clinical Recommendation
Do not use ICG fluorescence imaging as a primary method for margin assessment in breast-conserving surgery. The technique lacks guideline support, FDA approval for this indication, and sufficient evidence of clinical benefit. The high false-positive rate could lead to unnecessary tissue removal and worse cosmetic outcomes without improving oncologic safety.
If considering ICG in a research context, await results from the ongoing BREASTIFLU-1 trial 3 which is specifically designed to determine optimal dosing and timing protocols. Until then, rely on established margin assessment methods including intraoperative frozen section analysis and postoperative permanent pathology, with re-excision for positive margins as indicated by current surgical oncology guidelines 1.
Important Caveat:
The evidence cited here for ICG in flap perfusion assessment during mastectomy reconstruction 7, 8 represents a different application with stronger supporting data—this should not be confused with tumor margin assessment, which remains unvalidated.